Passage Bio, Inc. (PASG)
Largest Insider Buys in Sector
PASG Stock Price History Chart
PASG Stock Performance
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Insider Activity of Passage Bio, Inc.
Over the last 12 months, insiders at Passage Bio, Inc. have bought $1M and sold $51,585 worth of Passage Bio, Inc. stock.
On average, over the past 5 years, insiders at Passage Bio, Inc. have bought $23.52M and sold $270,521 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC (10 percent owner) — $35.06M.
The last purchase of 575,195 shares for transaction amount of $483,164 was made by ORBIMED ADVISORS LLC (10 percent owner) on 2023‑06‑28.
List of Insider Buy and Sell Transactions, Passage Bio, Inc.
| 2024-02-13 | Sale | Forman Mark S | CHIEF MEDICAL OFFICER | 1,638 0.0029% | $0.97 | $1,589 | +31.31% | |
| 2024-02-13 | Sale | Borthwick Kathleen | SVP, INTERIM CFO | 1,470 0.0026% | $0.97 | $1,426 | +31.31% | |
| 2024-01-02 | Sale | Cale Edgar B. | GC & Corporate Secretary | 15,813 0.0291% | $0.91 | $14,390 | +37.46% | |
| 2024-01-02 | Sale | Forman Mark S | Chief Medical Officer | 15,813 0.0291% | $0.91 | $14,390 | +37.46% | |
| 2024-01-02 | Sale | Borthwick Kathleen | SVP, Interim CFO | 10,672 0.0197% | $0.91 | $9,712 | +37.46% | |
| 2023-07-28 | Sale | King Simona | Chief Financial Officer | 11,453 0.021% | $0.88 | $10,079 | +6.36% | |
| 2023-06-28 | ORBIMED ADVISORS LLC | 10 percent owner | 575,195 1.0841% | $0.84 | $483,164 | +14.96% | ||
| 2023-06-27 | ORBIMED ADVISORS LLC | 10 percent owner | 617,382 1.144% | $0.84 | $518,601 | +12.72% | ||
| 2023-06-16 | Sale | Fotopoulos Alexandros | Chief Technical Officer | 4,052 0.0072% | $0.93 | $3,778 | -3.38% | |
| 2023-04-18 | Sale | King Simona | Chief Financial Officer | 2,053 0.0037% | $1.05 | $2,156 | -13.13% | |
| 2022-12-01 | Sale | Kapadia Sandip | director | 5,000 0.0092% | $1.19 | $5,965 | -17.48% | |
| 2022-11-22 | Sale | Fotopoulos Alexandros | Chief Technical Officer | 3,720 0.0076% | $1.33 | $4,948 | -17.38% | |
| 2022-09-19 | Sale | Toernsen Monika Maria | Chief Commercial Officer | 1,681 0.0029% | $1.51 | $2,539 | -32.92% | |
| 2022-05-03 | OrbiMed Capital GP VII LLC | 221,500 0.401% | $1.93 | $427,495 | -27.04% | |||
| 2022-03-21 | Goldsmith Bruce A | CEO and President | 10,000 0.0188% | $3.15 | $31,500 | -45.31% | ||
| 2022-01-20 | ORBIMED ADVISORS LLC | 10 percent owner | 50,800 0.0975% | $5.00 | $254,000 | -58.13% | ||
| 2022-01-19 | ORBIMED ADVISORS LLC | 10 percent owner | 43,300 0.0825% | $5.11 | $221,263 | -59.11% | ||
| 2022-01-18 | ORBIMED ADVISORS LLC | 10 percent owner | 114,700 0.2137% | $5.46 | $626,262 | -62.59% | ||
| 2022-01-14 | ORBIMED ADVISORS LLC | 10 percent owner | 10,300 0.0185% | $5.60 | $57,680 | -64.84% | ||
| 2022-01-13 | ORBIMED ADVISORS LLC | 10 percent owner | 41,800 0.0777% | $5.52 | $230,736 | -62.89% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 10 percent owner | 8034000 14.6553% | $0.91 | 10 | 0 | <0.0001% |
| Cale Edgar B. | GC & Corporate Secretary | 45995 0.0839% | $0.91 | 1 | 1 | <0.0001% |
| Forman Mark S | Chief Medical Officer | 48631 0.0826% | $0.91 | 0 | 2 | |
| Borthwick Kathleen | SVP, Interim CFO | 28466 0.0473% | $0.91 | 0 | 2 | |
| King Simona | Chief Financial Officer | 23994 0.0438% | $0.91 | 0 | 2 | |
| OrbiMed Capital GP VII LLC | 6537923 11.9263% | $0.91 | 1 | 0 | <0.0001% | |
| Heron Patrick J | 5009219 9.1376% | $0.91 | 1 | 0 | <0.0001% | |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 5009219 9.1376% | $0.91 | 1 | 0 | <0.0001% |
| Ratcliffe Liam | director | 2616630 4.7732% | $0.91 | 1 | 0 | <0.0001% |
| Woiwode Thomas | 933352 1.7026% | $0.91 | 1 | 0 | <0.0001% | |
| Versant Venture Capital VI, L.P. | 10 percent owner | 933352 1.7026% | $0.91 | 1 | 0 | <0.0001% |
| Yamada Tadataka | director | 656149 1.1969% | $0.91 | 1 | 0 | <0.0001% |
| Quigley Jill M. | Chief Operating Officer | 295284 0.5386% | $0.91 | 1 | 2 | <0.0001% |
| Fotopoulos Alexandros | Chief Technical Officer | 28693 0.0523% | $0.91 | 1 | 2 | <0.0001% |
| Countouriotis Athena | director | 18900 0.0345% | $0.91 | 2 | 0 | +16.32% |
| Goldsmith Bruce A | CEO and President | 15983 0.0292% | $0.91 | 3 | 0 | <0.0001% |
| Morris Richard Steven | Chief Financial Officer | 5454 0.0099% | $0.91 | 2 | 0 | <0.0001% |
| Islam Saqib | director | 5000 0.0091% | $0.91 | 1 | 0 | <0.0001% |
| Toernsen Monika Maria | Chief Commercial Officer | 3319 0.0061% | $0.91 | 0 | 1 | |
| Romano Gary | Chief Medical Officer | 0 0% | $0.91 | 0 | 1 | |
| Kapadia Sandip | director | 0 0% | $0.91 | 1 | 1 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $13.67M | 16.43 | 10.12M | 0% | +$0 | 0.28 | |
| Versant Ventures | $6.7M | 8.05 | 4.96M | 0% | +$0 | 9.33 | |
| Lynx1 Capital Management Lp | $6.54M | 7.86 | 4.85M | +1,178.06% | +$6.03M | 0.35 | |
| New Leaf Venture Partners | $3.37M | 4.05 | 2.5M | 0% | +$0 | 2.96 | |
| The Vanguard Group | $2.8M | 3.36 | 2.07M | +2.61% | +$71,085.59 | <0.0001 | |
| Tang Capital Management, LLC | $2.02M | 2.43 | 1.5M | -37.5% | -$1.22M | 0.01 | |
| Renaissance Technologies | $1.63M | 1.96 | 1.21M | -1.46% | -$24,059.69 | <0.01 | |
| Acadian Asset Management | $1.3M | 1.56 | 961,271 | +58.97% | +$480,764.04 | 0.01 | |
| BlackRock | $1.25M | 1.5 | 922,547 | -9.78% | -$135,021.55 | <0.0001 | |
| Millennium Management LLC | $1.17M | 1.4 | 865,739 | +9.84% | +$104,711.43 | <0.01 | |
| Bridgeway Capital Management | $750,792.00 | 0.9 | 556,142 | +9.78% | +$66,881.73 | 0.01 | |
| Acuitas Investments, LLC | $633,563.00 | 0.76 | 469,306 | +12.35% | +$69,622.19 | 0.33 | |
| Geode Capital Management | $518,913.00 | 0.62 | 384,278 | +15.68% | +$70,319.91 | <0.0001 | |
| Affinity Asset Advisors | $356,759.00 | 0.43 | 264,266 | New | +$356,759.00 | 0.06 | |
| Citadel Advisors LLC | $299,095.00 | 0.36 | 221,552 | -28.92% | -$121,717.27 | <0.0001 | |
| Fiduciary Trust Co | $290,250.00 | 0.35 | 215,000 | +86.96% | +$135,000.00 | 0.01 | |
| Two Sigma Advisers LP | $282,960.00 | 0.34 | 209,600 | -0.43% | -$1,215.00 | <0.0001 | |
| Two Sigma | $271,557.00 | 0.33 | 201,153 | 0% | +$0 | <0.0001 | |
| RBF Capital, LLC | $192,789.00 | 0.23 | 142,807 | 0% | +$0 | 0.01 | |
| Pale Fire Capital Se | $190,937.00 | 0.23 | 141,435 | -75.67% | -$593,758.92 | <0.01 | |
| State Street | $167,229.00 | 0.2 | 123,873 | 0% | +$0 | <0.0001 | |
| Tealwood Asset Management | $115,425.00 | 0.14 | 85,500 | 0% | +$0 | 0.03 | |
| Northern Trust | $113,760.00 | 0.14 | 84,267 | +9.6% | +$9,965.66 | <0.0001 | |
| Xtx Topco Ltd | $58,000.00 | 0.07 | 42,963 | +51.12% | +$19,620.88 | <0.01 | |
| Goldman Sachs | $36,388.00 | 0.04 | 26,954 | +0.22% | +$78.30 | <0.0001 | |
| Virtu Financial Llc | $34,000.00 | 0.04 | 25,425 | -62.45% | -$56,538.29 | <0.01 | |
| Cresset Asset Management Llc | $32,029.00 | 0.04 | 23,725 | 0% | +$0 | <0.0001 | |
| Marshall Wace | $29,687.00 | 0.04 | 21,990 | New | +$29,687.00 | <0.0001 | |
| Hightower Advisors | $29,000.00 | 0.04 | 21,763 | -2.25% | -$667.60 | <0.0001 | |
| Fidelity Investments | $28,445.00 | 0.03 | 21,070 | -66.03% | -$55,284.82 | <0.0001 | |
| Morgan Stanley | $18,679.00 | 0.02 | 13,837 | 0% | +$0 | <0.0001 | |
| Barclays | $18,000.00 | 0.02 | 13,153 | 0% | +$0 | <0.0001 | |
| Cubist Systematic Strategies | $15,242.00 | 0.02 | 11,290 | New | +$15,242.00 | <0.0001 | |
| Citigroup | $5,358.00 | 0.01 | 3,969 | -17.28% | -$1,119.12 | <0.0001 | |
| Federated Hermes | $1,057.00 | <0.01 | 783 | New | +$1,057.00 | <0.0001 | |
| Royal Bank of Canada | $1,000.00 | <0.01 | 500 | +31.93% | +$242.00 | <0.0001 | |
| RhumbLine Advisers | $1,057.00 | <0.01 | 783 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $417.00 | <0.01 | 309 | +1.65% | +$6.75 | <0.0001 | |
| JPMorgan Chase | $369.00 | <0.01 | 273 | -80.17% | -$1,492.22 | <0.0001 | |
| Tower Research Capital | $46.00 | <0.01 | 34 | New | +$46.00 | <0.0001 | |
| CWM LLC | $0 | <0.01 | 5 | 0% | +$0 | <0.0001 | |
| Bank of America | $1.00 | <0.01 | 1 | -96.88% | -$31.00 | <0.0001 | |
| Group One Trading | $63.00 | <0.01 | 47 | 0% | +$0 | <0.0001 | |
| Qube Research & Technologies | $5.00 | <0.01 | 4 | 0% | +$0 | <0.0001 | |
| Tsfg Llc | $0 | <0.01 | 100 | 0% | +$0 | <0.0001 | |
| Advisor Group Holdings Inc | $293.00 | <0.01 | 217 | 0% | +$0 | <0.0001 |